NCT03358719View on ClinicalTrials.gov

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

March 27, 2018

Primary Completion Date

February 27, 2020

Study Completion Date

August 25, 2021

Conditions
Acute Myeloid LeukemiaBlasts 30 Percent or Less of Bone Marrow Nucleated CellsChronic Myelomonocytic LeukemiaHigh Risk Myelodysplastic SyndromeMyelodysplastic SyndromeRefractory Anemia
Interventions
BIOLOGICAL

DEC-205/NY-ESO-1 Fusion Protein CDX-1401

Given intracutaneously

DRUG

Decitabine

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Nivolumab

Given IV

DRUG

Poly ICLC

Given SC

Trial Locations (1)

14263

Roswell Park Cancer Institute, Buffalo

Sponsors

Collaborators (1)

Celldex Therapeutics
All Listed Sponsors
collaborator

Celldex Therapeutics

INDUSTRY

lead

Roswell Park Cancer Institute

OTHER

NCT03358719 - DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter